The spectacular gain in Contemporary Amperex Technology (CATL) shares since its Hong Kong listing faces a reality check this week:…
Read More »Jiangsu Hengrui Pharmaceuticals
The ferocity of China’s biopharmaceutical investment boom this year – fuelled by record-breaking licensing of commercial rights to global giants…
Read More »
American pharmaceutical giant Pfizer’s up to US$7.3 billion acquisition of next-generation weight loss drugs developer Metsera will encourage more research…
Read More »
Biotech firm Ascletis Pharma said ASC47, its muscle-preserving weight loss drug candidate, could boost the efficacy of the popular anti-obesity…
Read More »
GIC, Millennium Management and Hillhouse Investment are among heavyweights that are set to invest in Zijin Gold International’s initial public…
Read More »
In the first of a two-part series about Hong Kong’s market for initial public offerings, Zhang Shidong and Ao Yulu…
Read More »
Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group, two of China’s largest drug makers, are expected to report significantly improved profits,…
Read More »
Chinese heating systems supplier Zhejiang Sanhua Intelligent Controls had a tepid trading debut in Hong Kong on Monday, with investors…
Read More »
Trading under code 3288, Haitian’s shares first changed hands on Thursday at HK$37.50, up 3.3 per cent from their offer…
Read More »
Foshan Haitian Flavouring and Food Company, the largest listed condiment producer in mainland China, is seeking to raise up to…
Read More »